Singapore, Singapore

Bing Lim

This inventor holds 7 USPTO granted patents and 6 published patent applications and 2 EPO patents. Top assignee: Agency for Science, Technology and Research. Active years: 2014-2024.

USPTO Granted Patents = 7 

% Patents Active = 71.4

 

Average Co-Inventor Count = 3.4

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2014-2024

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Bing Lim

Introduction

Bing Lim is a prominent inventor based in Singapore, known for his significant contributions to cancer treatment methodologies. With a total of seven patents to his name, he has made strides in developing therapeutic protocols aimed at improving patient outcomes in cancer care.

Latest Patents

Among his latest patents is a method of treating a methionine-dependent cancer. This invention outlines a therapeutic protocol designed to treat subjects diagnosed with cancer. It emphasizes a method for reducing the risk of cancer recurrence following anti-cancer therapy, showcasing Lim's commitment to advancing medical science.

Career Highlights

Bing Lim is affiliated with the Agency for Science, Technology and Research, where he applies his expertise in cancer research. His work has garnered attention for its innovative approach to addressing complex medical challenges.

Collaborations

He collaborates with esteemed colleagues such as Zhenxun Wang and Wai Leong Tam, contributing to a dynamic research environment focused on cancer treatment advancements.

Conclusion

Bing Lim's innovative work in cancer treatment exemplifies the impact of dedicated research and collaboration in the medical field. His patents reflect a commitment to improving therapeutic strategies for cancer patients, marking him as a significant figure in contemporary medical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…